GH PE Ratio & Valuation,Is GH Overvalued

GH Relative Valuation

GH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GH is overvalued; if below, it's undervalued.

Historical Valuation

Guardant Health Inc (GH) is now in the Fair zone, suggesting that its current forward PS ratio of 11.39 is considered Fairly compared with the five-year average of -20.01. The fair price of Guardant Health Inc (GH) is between 15.54 to 174.62 according to relative valuation methord.

Relative Value

Fair Zone

15.54-174.62

Current Price：102.07

Fair

-62.39

-88.88

EV/EBITDA

Guardant Health Inc. (GH) has a current EV/EBITDA of -88.88. The 5-year average EV/EBITDA is -22.30. The thresholds are as follows: Strongly Undervalued below -55.89, Undervalued between -55.89 and -39.09, Fairly Valued between -5.51 and -39.09, Overvalued between -5.51 and 11.28, and Strongly Overvalued above 11.28. The current Forward EV/EBITDA of -88.88 falls within the Strongly Undervalued range.

-37.50

EV/EBIT

Guardant Health Inc. (GH) has a current EV/EBIT of -37.50. The 5-year average EV/EBIT is -15.80. The thresholds are as follows: Strongly Undervalued below -36.88, Undervalued between -36.88 and -26.34, Fairly Valued between -5.27 and -26.34, Overvalued between -5.27 and 5.27, and Strongly Overvalued above 5.27. The current Forward EV/EBIT of -37.50 falls within the Strongly Undervalued range.

11.39

Guardant Health Inc. (GH) has a current PS of 11.39. The 5-year average PS is 12.26. The thresholds are as follows: Strongly Undervalued below -9.90, Undervalued between -9.90 and 1.18, Fairly Valued between 23.34 and 1.18, Overvalued between 23.34 and 34.42, and Strongly Overvalued above 34.42. The current Forward PS of 11.39 falls within the Historic Trend Line -Fairly Valued range.

-99.32

P/OCF

Guardant Health Inc. (GH) has a current P/OCF of -99.32. The 5-year average P/OCF is -26.97. The thresholds are as follows: Strongly Undervalued below -71.19, Undervalued between -71.19 and -49.08, Fairly Valued between -4.87 and -49.08, Overvalued between -4.87 and 17.24, and Strongly Overvalued above 17.24. The current Forward P/OCF of -99.32 falls within the Strongly Undervalued range.

-60.76

P/FCF

Guardant Health Inc. (GH) has a current P/FCF of -60.76. The 5-year average P/FCF is -22.27. The thresholds are as follows: Strongly Undervalued below -57.06, Undervalued between -57.06 and -39.66, Fairly Valued between -4.87 and -39.66, Overvalued between -4.87 and 12.53, and Strongly Overvalued above 12.53. The current Forward P/FCF of -60.76 falls within the Strongly Undervalued range.

Guardant Health Inc (GH) has a current Price-to-Book (P/B) ratio of -35.98. Compared to its 3-year average P/B ratio of -240.44 , the current P/B ratio is approximately -85.03% higher. Relative to its 5-year average P/B ratio of -136.96, the current P/B ratio is about -73.73% higher. Guardant Health Inc (GH) has a Forward Free Cash Flow (FCF) yield of approximately -1.99%. Compared to its 3-year average FCF yield of -9.13%, the current FCF yield is approximately -78.16% lower. Relative to its 5-year average FCF yield of -6.98% , the current FCF yield is about -71.43% lower.

-35.98

P/B

Median3y

-240.44

Median5y

-136.96

-1.99

FCF Yield

Median3y

-9.13

Median5y

-6.98

Competitors Valuation Multiple

The average P/S ratio for GH's competitors is 2.99, providing a benchmark for relative valuation. Guardant Health Inc Corp (GH) exhibits a P/S ratio of 11.39, which is 281.42% above the industry average. Given its robust revenue growth of 38.50%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of GH increased by 234.11% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -9.52 to -31.76.

The secondary factor is the Revenue Growth, contributed 38.50%to the performance.

Overall, the performance of GH in the past 1 year is driven by P/E Change. Which is more unsustainable.

38.50%

191.48M → 265.20M

Revenue Growth

-37.88%

-56.28 → -34.96

Margin Expansion

233.49%

-9.52 → -31.76

P/E Change

234.11%

30.55 → 102.07

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Guardant Health Inc (GH) currently overvalued or undervalued?

What is Guardant Health Inc (GH) fair value?

GH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Guardant Health Inc (GH) is between 15.54 to 174.62 according to relative valuation methord.

How does GH's valuation metrics compare to the industry average?

What is the current P/B ratio for Guardant Health Inc (GH) as of Dec 15 2025?

As of Dec 15 2025, Guardant Health Inc (GH) has a P/B ratio of -35.98. This indicates that the market values GH at -35.98 times its book value.

What is the current FCF Yield for Guardant Health Inc (GH) as of Dec 15 2025?

As of Dec 15 2025, Guardant Health Inc (GH) has a FCF Yield of -1.99%. This means that for every dollar of Guardant Health Inc’s market capitalization, the company generates -1.99 cents in free cash flow.

What is the current Forward P/E ratio for Guardant Health Inc (GH) as of Dec 15 2025?

As of Dec 15 2025, Guardant Health Inc (GH) has a Forward P/E ratio of -62.39. This means the market is willing to pay $-62.39 for every dollar of Guardant Health Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Guardant Health Inc (GH) as of Dec 15 2025?

As of Dec 15 2025, Guardant Health Inc (GH) has a Forward P/S ratio of 11.39. This means the market is valuing GH at $11.39 for every dollar of expected revenue over the next 12 months.

GH Valuation